# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Flannery O'Connor (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML046-SYN
- Date: 2026-07-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Augusta Pemberton-Diallo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month review of lupus nephritis. **S**

## History of present illness

Ms. O'Connor is thirteen weeks into treatment. Her joint pain and swelling settled within three weeks and the facial rash has faded with sun protection; she has had no fevers. She takes prednisone 10 mg a day, reached a month ago, mycophenolate 1000 mg twice daily (loose stools in the first two weeks, since settled), weekly belimumab by her own injection, hydroxychloroquine, and losartan. The rheumatology blood counts, weekly for the first month and twice monthly since, have stayed normal, with white cells between 4.8 and 7.9 and normal liver tests. The bladder infection in June grew Escherichia coli sensitive to nitrofurantoin and cleared after seven days. Her baseline eye examination a month ago was normal. She has gained 3.4 kg and sleeps less well on the days after a dose reduction. She writes five mornings a week. **S**

| Element | Detail |
|---|---|
| Interval change | Arthritis, rash, and fevers resolved; cystitis in June resolved |
| Medicines | Prednisone 10 mg; mycophenolate 2 g a day; belimumab weekly; hydroxychloroquine; losartan |
| Monitoring | Blood counts and liver tests normal; eye examination normal |
| Work | Writing five mornings a week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Weight up 3.4 kg; no fever |
| Musculoskeletal | Negative | No joint pain; no hip, groin, or knee pain |
| Integumentary | Negative | Rash gone; hair shedding less |
| Gastrointestinal | Negative | Stools normal now |
| Genitourinary | Negative | No urinary symptoms |
| Psychiatric | Positive | Poor sleep on some nights; mood good; PHQ-9 4 |

6 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day **S**
- Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term **S**
- Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure **S**
- Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months **S**
- Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily **S**
- Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 63.4 kg; BMI 22.5 kg/m². All vital signs are synthetic.

Hemoglobin: 12.1 g/dL; White cell count: 5.2 10*3/uL; Lymphocytes: 1 10*3/uL; Platelets: 212 10*3/uL; Creatinine: 0.8 mg/dL; eGFR: 101 mL/min/1.73 m²; Potassium: 4.4 mmol/L; Albumin: 3.8 g/dL; ALT: 22 U/L; Urine protein-to-creatinine ratio: 0.9 g/g (high); Urine red cells: 6 /[HPF] (high); Anti-dsDNA: 72 [IU]/mL (high); Complement C3: 84 mg/dL (low); Complement C4: 13 mg/dL; 25-hydroxyvitamin D: 36 ng/mL; Total cholesterol: 212 mg/dL (high); HDL cholesterol: 58 mg/dL; LDL cholesterol: 128 mg/dL (high); Triglycerides: 130 mg/dL; HbA1c: 5.3%; PHQ-9: 4; Joint pain (0 to 10): 1. All results are synthetic.

## Change since baseline

- Hemoglobin: 11 g/dL (low) at baseline, 12.1 g/dL at this visit **S**
- White cell count: 3.3 10*3/uL (low) at baseline, 5.2 10*3/uL at this visit **S**
- Lymphocytes: 0.8 10*3/uL (low) at baseline, 1 10*3/uL at this visit **S**
- Platelets: 138 10*3/uL (low) at baseline, 212 10*3/uL at this visit **S**
- Creatinine: 0.8 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR: 101 mL/min/1.73 m² at baseline, 101 mL/min/1.73 m² at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Albumin: 3.3 g/dL (low) at baseline, 3.8 g/dL at this visit **S**
- ALT: 19 U/L at baseline, 22 U/L at this visit **S**
- Urine protein-to-creatinine ratio: 1.6 g/g (high) at baseline, 0.9 g/g (high) at this visit **S**
- Urine red cells: 18 /[HPF] (high) at baseline, 6 /[HPF] (high) at this visit **S**
- PHQ-9: 7 at baseline, 4 at this visit **S**
- Joint pain (0 to 10): 6 at baseline, 1 at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; slight fullness of the face |
| Skin | No malar rash; no mouth ulcers |
| Musculoskeletal | No synovitis; full, painless hip movement |
| Cardiovascular | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Class III lupus nephritis on treatment** (M32.14). The protein-to-creatinine ratio has halved, from 1.8 to 0.9 g/g, with fewer red cells (6 per high-power field) and stable creatinine 0.8. Anti-dsDNA has fallen from 186 to 72 and complements are rising (C3 84, C4 13). She is responding and on track for a complete response. **S**
   - Continue mycophenolate 1000 mg twice daily, belimumab weekly, hydroxychloroquine, and losartan.
   - Prednisone to 7.5 mg next month and 5 mg by six months.
   - Blood counts monthly from now.
2. **Systemic lupus erythematosus** (M32.19). Clinically quiet outside the kidney. Cardiovascular risk: LDL 128 mg/dL, total cholesterol 212, HDL 58 on prednisone; HbA1c 5.3 percent; blood pressure 122/78; never smoker. **S**
   - No statin now; recheck lipids at one year on a low prednisone dose.
   - Recombinant zoster vaccine dose 2 today.
3. **Glucocorticoids: bone and side effects** (Z79.52). Vitamin D 36 on replacement; no hip pain; weight gain and poor sleep expected to ease as the dose falls. **S**
   - Continue vitamin D3.
   - Report any hip, groin, or knee pain at once.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Urine protein-to-creatinine ratio and urine sediment | Every 3 months during active treatment | Completed today | 0.9 g/g, from 1.8; 6 red cells per high-power field |
| Laboratory | Creatinine, eGFR, and albumin | Every 3 months during active treatment | Completed today | Creatinine 0.8, eGFR 101, albumin 3.8 |
| Laboratory | Anti-dsDNA, C3, and C4 | Every 3 months during active treatment | Completed today | Anti-dsDNA 72; C3 84; C4 13 |
| Laboratory | Blood count and liver tests on mycophenolate | Weekly for a month, twice monthly for two months, then monthly | Completed today | White cells 5.2, lymphocytes 1.0, hemoglobin 12.1, platelets 212; ALT 22; earlier rheumatology counts normal |
| Laboratory | Potassium and creatinine after starting losartan | 2 to 4 weeks after starting | Deferred | Missed, a deviation from the protocol: the check due two to four weeks after losartan was started was not drawn, because the standing rheumatology orders were for blood counts only. The first potassium, at the sick visit seven and a half weeks after starting, was 4.6 with creatinine unchanged at 0.8, so no harm resulted. Corrective action: a basic metabolic panel was added to the standing orders at that visit, and any dose change will be followed by a check at two weeks |
| Laboratory | Potassium | With each kidney panel on losartan | Completed today | 4.4 mmol/L |
| Examination | Blood pressure | Every visit | Completed today | 122/78 mmHg, at target |
| Laboratory | Glucose and lipids on glucocorticoids | At three months | Completed today | HbA1c 5.3 percent; total cholesterol 212, HDL 58, LDL 128, triglycerides 130 |
| Laboratory | 25-hydroxyvitamin D | After repletion | Completed today | 36 ng/mL |
| Examination | Avascular necrosis symptoms | Every visit | Completed today | No hip, groin, or knee pain |
| Medication safety | Glucocorticoid dose | Every visit | Completed today | Prednisone 10 mg; on schedule for 5 mg or less by six months |
| Medication safety | Hydroxychloroquine baseline eye examination | Within the first year | Up to date | A month ago: fundus, OCT, and visual fields normal |
| Medication safety | Recombinant zoster vaccine dose 2 | 1 to 2 months after dose 1 | Completed today | Given today |
| Medication safety | Contraception on mycophenolate | Every visit | Up to date | Intrauterine system in place |
| Survey | Mood on belimumab (PHQ-9) | Periodically | Completed today | PHQ-9 4 |
| Survey | Joint pain score | Every visit | Completed today | 1 of 10 |
| Self-management | Sun protection and writing schedule | Every visit | Completed today | Sunscreen daily; writing five mornings a week |

## Goal progress

- Establish the diagnosis within two weeks and hear it directly, in plain words. Outcome by 2026-04-22: Told directly at nine days that she has systemic lupus erythematosus, with the reasons and a written summary. **S**
- Renal response: urine protein-to-creatinine ratio halved by three months and below 0.5 g/g with stable kidney function by six to twelve months. In progress; target 2026-10-26. **S**
- Prednisone 5 mg a day or less by six months, with withdrawal considered later. In progress; target 2026-10-26. **S**
- Write at least four mornings a week through treatment. In progress; target 2026-12-31. **S**
- No unplanned pregnancy on mycophenolate; plan any pregnancy for a time of quiet disease on compatible medicines. In progress; target 2026-12-31. **S**

## Guideline basis

- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023), EULAR
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024), American College of Rheumatology
- 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022), American College of Rheumatology
- CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026), U.S. National Library of Medicine, DailyMed
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease and hypertension monographs (2026), Aether Forge

## Follow-up

- Prednisone to 7.5 mg next month. Rheumatology blood counts monthly. Preventive visit in October. Six-month review. **S**
- Next scheduled visit 2026-10-05: adult preventive visit. **S**
